MedGenesis Therapeutix Inc. (MedGenesis) is a privately-held Canadian biopharmaceutical company committed to developing and commercializing highly innovative treatments for patients with serious neurologic disease.
MedGenesis' lead program, glial cell-line derived neurotrophic factor (GDNF), has recently completed Phase 2 clinical studies. The primary target indication for GDNF is Parkinson's disease, a progressive neurodegenerative disorder for which current treatment options are purely symptomatic. GDNF has the potential to become the world's first disease modifying therapy for Parkinson's disease. The program is the first to use MedGenesis' proprietary intermittent convection-enhanced delivery paradigm for targeted, local drug administration to the affected brain area.